Effect of intravesical administration of tumor necrosis serum and human recombinant tumor necrosis factor on a murine bladder tumor.
The effect of intravesical administration of tumor necrosis factor (TNF) on the implantability and growth of bladder cancer was studied using the murine tumor model, MBT-2. Crude TNF was prepared from serum (TNS) of BCG infected rats after injection of endotoxin or the recombinant product of human TNF-alpha was used. Treatment was begun 24 hr. or seven days after tumor instillation and repeated three times. Tumor implantability and tumor weight were determined on day 21. Low dose TNF (200 U), given in the form of TNS, failed to suppress the growth of established tumors (seven-day tumor). It did, however, significantly reduce tumor implantability. The growth of seven-day tumors was significantly suppressed by administration of higher dose of TNF (3,700 U) given in recombinant form.
D000283:Administration, Intravesical; D000818:Animals; D003603:Cytotoxins / Q000008:administration & dosage; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage* / Q000627:therapeutic use; D051379:Mice; D051381:Rats; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D003603:Cytotoxins; D006023:Glycoproteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha